Saeedi Tehrani Saeedeh, Hashemi Akram, Madani Mansureh, Forouzandeh Mina
Assistant Professor, Department of Medical Ethics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Researcher, PhD in Medical Ethics.
J Med Ethics Hist Med. 2020 Dec 21;13:27. doi: 10.18502/jmehm.v13i27.5044. eCollection 2020.
Maintaining confidentiality, both in national and international codes of ethics, is considered an important principle in healthcare and the medical profession for both patients and physicians. This case-report article focused on a real case. Based on the request of the Iranian Blood Transfusion Organization (IBTO) for plasma donation from recovered COVID-19 patients, we asked the names and personal information of those patients from hospitals affiliated with Iran University of Medical Sciences (IUMS) and arranged for the subjects to be referred to the Medical Ethics Department of IUMS for consultation during the COVID-19 pandemic. Various ethical and legal aspects of this case were discussed in a special meeting, and practical solutions were then provided considering the limits of confidentiality and conditions for ethical access to patients' information during a pandemic. Since plasma therapy is not a definitive cure for COVID-19 and considering the ethical and legal points presented in this article, it is not recommended to announce the names of patients in the early stages. Given the potential impacts of the procedure and the possibility of patients being cured, however, their consent should be obtained in different situations and, if necessary, providing information to patients or educating them should be considered.
在国家和国际伦理准则中,保密对于医疗保健领域以及医患双方而言,都是一项重要原则。这篇病例报告文章聚焦于一个真实案例。应伊朗输血组织(IBTO)关于康复的新冠患者血浆捐献的请求,我们向伊朗医科大学(IUMS)附属的医院询问了这些患者的姓名和个人信息,并在新冠疫情期间安排这些受试者前往IUMS医学伦理部门进行咨询。在一次特别会议上讨论了该案例的各种伦理和法律问题,随后在考虑保密限制以及疫情期间获取患者信息的伦理条件的情况下,提供了切实可行的解决方案。由于血浆疗法并非新冠的确定性治疗方法,并且考虑到本文提出的伦理和法律要点,不建议在早期公布患者姓名。然而,鉴于该程序的潜在影响以及患者治愈的可能性,在不同情况下应征得他们的同意,如有必要,应考虑向患者提供信息或对其进行教育。